Skip to main content

Advertisement

SpringerLink
Log in

Elevated levels of serum sclerostin are linked to adverse cardiovascular outcomes in peritoneal dialysis patients

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the correlation between elevated serum sclerostin levels and chronic kidney disease outcomes for patients receiving peritoneal dialysis (PD).

Methods

We performed a prospective observational study in stable PD patients. Serum sclerostin levels were determined via enzyme immunoassay, and median levels of sclerostin were used to divide patients into high and low sclerostin groups. New-onset cardiovascular events (CVEs) and cardiovascular mortality were evaluated during a 6-year follow-up period.

Results

Ninety-eight patients [mean age 52.5 ± 10.9 years, 49% males, 21.4% diabetic, median dialysis vintage 40.7 (range 17.9–72.2) months] were recruited. Compared with those in the low sclerostin group, patients in the high sclerostin group demonstrated higher levels of total-cholesterol, NT-proBNP, and osteoprotegerin (all P < 0.05). During the 6-year study period, 25 CVEs and 17 cardiovascular deaths occurred in the high sclerostin group, whereas 11 CVEs and four cardiovascular deaths occurred in the low sclerostin group. A Cox regression analysis determined that high sclerostin levels significantly increased the risk for CVEs (HR 2.475, 95% CI 1.116–5.489, P = 0.026) and cardiovascular death (HR 3.484, 95% CI1.134–10.706, P = 0.029), after multiple adjustments were made.

Conclusions

Our data suggest that high sclerostin levels may predict the onset of CVEs and cardiovascular mortality among PD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Collins AJ et al (2009) United States renal data system 2008 annual data report. Am J Kidney Dis 53(1 Suppl):S1–S374

    Google Scholar 

  2. Nitta K (2011) Vascular calcification in patients with chronic kidney disease. Ther Apher Dial 15(6):513–521

    Article  CAS  PubMed  Google Scholar 

  3. Raggi P, Kleerekoper M (2008) Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 3(3):836–843

    Article  CAS  PubMed  Google Scholar 

  4. Baron R, Rawadi G (2007) Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep 5(2):73–80

    Article  PubMed  Google Scholar 

  5. Li X et al (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23(6):860–869

    Article  PubMed  Google Scholar 

  6. Fang Y et al (2014) Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int 85(1):142–150

    Article  CAS  PubMed  Google Scholar 

  7. Kramann R et al (2013) Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol Dial Transplant 28(4):856–868

    Article  CAS  PubMed  Google Scholar 

  8. Claes KJ et al (2013) Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 98(8):3221–3228

    Article  CAS  PubMed  Google Scholar 

  9. de Oliveira RB et al (2013) Disturbances of Wnt/beta-catenin pathway and energy metabolism in early CKD: effect of phosphate binders. Nephrol Dial Transplant 28(10):2510–2517

    Article  PubMed  Google Scholar 

  10. Cejka D et al (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99(1):248–255

    Article  CAS  PubMed  Google Scholar 

  11. Kanbay M et al (2016) Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol 48(12):2029–2042

    Article  CAS  PubMed  Google Scholar 

  12. Kanbay M et al (2014) Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab 99(10):E1854–E1861

    Article  CAS  PubMed  Google Scholar 

  13. Goncalves FL et al (2014) Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol 15:190

    Article  PubMed  PubMed Central  Google Scholar 

  14. Desjardins L et al (2014) Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol Ther 10(6):463–470

    Article  PubMed  Google Scholar 

  15. Yang CY et al (2015) Circulating Wnt/beta-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant 30(8):1356–1363

    Article  PubMed  Google Scholar 

  16. Jean G et al (2016) High serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron 132(3):181–190

    Article  CAS  PubMed  Google Scholar 

  17. Payne RB et al (1973) Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4(5893):643–646

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Orrell DH (1971) Albumin as an aid to the interpretation of serum calcium. Clin Chim Acta 35(2):483–489

    Article  CAS  PubMed  Google Scholar 

  19. Berry EM et al (1973) Variation in plasma calcium with induced changes in plasma specific gravity, total protein, and albumin. Br Med J 4(5893):640–643

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Xu Q et al (2015) Association of pulmonary hypertension with mortality in incident peritoneal dialysis patients. Perit Dial Int 35(5):537–544

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Gooi JH et al (2010) Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone 46(6):1486–1497

    Article  CAS  PubMed  Google Scholar 

  22. Ferreira JC et al (2013) Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease–role of sclerostin? PLoS ONE 8(11):e79721

    Article  PubMed  PubMed Central  Google Scholar 

  23. Drake MT et al (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95(11):5056–5062

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bellido T et al (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146(11):4577–4583

    Article  CAS  PubMed  Google Scholar 

  25. Pelletier S et al (2013) The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 8(5):819–823

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Thambiah S et al (2012) Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 90(6):473–480

    Article  CAS  PubMed  Google Scholar 

  27. Morena M et al (2015) Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant 30(8):1345–1356

    Article  CAS  PubMed  Google Scholar 

  28. Koo HM et al (2011) Elevated osteoprotegerin is associated with inflammation, malnutrition and new onset cardiovascular events in peritoneal dialysis patients. Atherosclerosis 219(2):925–930

    Article  CAS  PubMed  Google Scholar 

  29. Nakashima A et al (2011) Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. Osteoporos Int 22(6):1695–1701

    Article  CAS  PubMed  Google Scholar 

  30. Kuzniewski M et al (2016) Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure. Adv Med Sci 61(2):269–275

    Article  PubMed  Google Scholar 

  31. Magoori K et al (2003) Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. J Biol Chem 278(13):11331–11336

    Article  CAS  PubMed  Google Scholar 

  32. Fujino T et al (2003) Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci USA 100(1):229–234

    Article  CAS  PubMed  Google Scholar 

  33. Behari J et al (2010) Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J Pathol 176(2):744–753

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Urano T et al (2012) Association of circulating sclerostin levels with fat mass and metabolic disease–related markers in Japanese postmenopausal women. J Clin Endocrinol Metab 97(8):E1473–E1477

    Article  CAS  PubMed  Google Scholar 

  35. Yamada S et al (2015) Factors associated with serum soluble inhibitors of Wnt-beta-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis. Nephrology (Carlton) 20(9):639–645

    Article  CAS  Google Scholar 

  36. Sabbagh Y et al (2012) Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 27(8):1757–1772

    Article  CAS  PubMed  Google Scholar 

  37. Drechsler C et al (2015) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 30(2):288–293

    Article  CAS  PubMed  Google Scholar 

  38. Poole KE et al (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19(13):1842–1844

    Article  CAS  PubMed  Google Scholar 

  39. Zhu D et al (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 6(5):e19595

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Brandenburg VM et al (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 14:219

    Article  PubMed  PubMed Central  Google Scholar 

  41. Koos R et al (2013) Sclerostin as a potential novel biomarker for aortic valve calcification: an in vivo and ex vivo study. J Heart Valve Dis 22(3):317–325

    PubMed  Google Scholar 

  42. Hampson G et al (2013) The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 56(1):42–47

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was supported through grants from the National Nature Science Foundation of China (81670691, 81370864), and the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant (20152211).

Author information

Authors and Affiliations

  1. Department of Nephrology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Road, Shanghai, 200127, People’s Republic of China

    Li Gong, Dongxia Zheng, Jiangzi Yuan, Liou Cao, Zhaohui Ni & Wei Fang

Authors
  1. Li Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dongxia Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiangzi Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liou Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhaohui Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wei Fang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study received ethics approval from the ethics committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University. It was performed in accordance with the ethical standards of the institutional and/or national research committees as well as with the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was procured from all individual patients who participated in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gong, L., Zheng, D., Yuan, J. et al. Elevated levels of serum sclerostin are linked to adverse cardiovascular outcomes in peritoneal dialysis patients. Int Urol Nephrol 50, 955–961 (2018). https://doi.org/10.1007/s11255-018-1795-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-018-1795-z

Keywords

Search

Navigation